Information Provided By: 
Fly News Breaks for September 27, 2018
EGRX
Sep 27, 2018 | 06:17 EDT
Mizuho analyst Irina Koffler sees downside risk to Eagle Pharmaceuticals shares associated with the pending data release from the fulvestrant bioequivalence trial, expected in mid-October. She views the commercial opportunity for the product as modest, and model $8M in sales in 2022. Even if Eagle discloses positive data, investor uncertainty about launch execution in a "crowded generic market" could keep shares range-bound, Koffler tells investors in a research note. She reiterates a Neutral rating on the shares with a $65 price target.
News For EGRX From the Last 2 Days
There are no results for your query EGRX
